Merck boosts EPS by 33% in Q4

Wednesday, 05. February 2020 12:48

American pharmaceutical giant Merck &Co. Inc. said on Wednesday that its earnings per share (EPS) jumped 33% in the quarter ending December 31, 2019, to reach $0.92, similarly as net income, which rose by 29% to $2.36 billion. Meanwhile, net sales added 8% on an annual basis in the fourth quarter, amounting to $11.87 billion.

Full-year results showed an increase of 11% in total net sales and a surge of 64% in EPS. Net income in 2019 was $9.84 billion, 58% higher than in 2018.

"As evidenced by our results and our 2020 guidance, Merck had an extraordinary year and is in a position of operational and financial strength. It is this position of strength, born of our focused execution, that gives us the confidence to spin off our Women’s Health, trusted Legacy Brands and Biosimilar products into a new company, which will position us to deliver even greater value to patients and shareholders," said CEO Kenneth C. Frazier.

Related Links: Merck KGaAMerck & Co. Inc.
Breaking the News / NI